Objective: To evaluate the results of the introduction of MSCs on the non-motor symptoms in patients with PD within 12 months after the cell therapy.

Background: The use of autologous mesenchymal multipotent stem cells (MSCs) is a promising area of cell therapy for many neurological diseases, including Parkinson disease (PD). Our previous data demonstrate a decrease in the severity of motor and non-motor symptoms of the disease in the early post-transplant period. The clinical study that started in January 2019 so far included 21 PD patients that received the cell therapy and 13 patients from the control group, who received placebo therapy.

Method: MSCs were injected to twenty one patients with PD via intravenous and tandem (intranasal + intravenous) injections. Placebo therapy (isotonic saline) was performed to thirteen patients with PD via tandem injection.  Effectiveness of the therapy was evaluated three, six, nine and twelve months after the cell therapy. The assessment of non-motor functions was carried out with the following scales: HDRS (Hamilton Depression Rating Scale), ESS (the Epworth Sleepiness Scale), NMSQ (Non-Motor Symptoms Questionnaire).

Results: The severity of the non-motor symptoms of PD in the long-term follow-up began to increase by the end of the observation period.

Conclusion: According to our results, the therapeutic effect of the introduction of MSCs on the non-motor symptoms in patients with PD decreases after the 12-month period.

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/assessment-of-non-motor-symptoms-of-parkinsons-disease-in-the-long-term-follow-up-after-the-cell-therapy/